Jupiter Neurosciences signs exclusive US license for PharmAla's ALA-002 MDMA program

JUPITER NEUROSCIENCES, INC.

Upfront payment of $3.33M: $1.5M cash (net of $600K escrow) plus $1.83M in Jupiter common stock.
Development milestones up to $23.33M: $3.33M on Phase 3 first dosing, $20M on first FDA NDA approval.
Commercialization milestones up to $73.33M: $10M at $333M net sales, $30M at $1B, $33.33M at $2B.
Royalty of 3% on net sales in the Territory, beginning after the third commercialization milestone is payable.
Exclusive license for all human therapeutic uses in the US; Jupiter must use commercially reasonable efforts to develop and commercialize.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.